Insider Selling: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Sells $97,888.70 in Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $9.10, for a total transaction of $97,888.70. Following the completion of the sale, the chief financial officer now owns 226,097 shares in the company, valued at $2,057,482.70. This represents a 4.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Mineralys Therapeutics Stock Down 2.7 %

NASDAQ MLYS opened at $9.24 on Friday. The firm’s 50 day moving average is $12.18 and its 200-day moving average is $12.45. The company has a market capitalization of $459.87 million, a PE ratio of -2.83 and a beta of 1.49. Mineralys Therapeutics, Inc. has a 12-month low of $7.95 and a 12-month high of $16.91.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its quarterly earnings results on Monday, November 11th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.30). During the same period in the previous year, the company earned ($0.57) EPS. As a group, sell-side analysts expect that Mineralys Therapeutics, Inc. will post -3.63 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a research report on Tuesday, November 12th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new position in shares of Mineralys Therapeutics during the 3rd quarter worth approximately $110,000. China Universal Asset Management Co. Ltd. increased its holdings in Mineralys Therapeutics by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,564 shares of the company’s stock worth $116,000 after buying an additional 3,732 shares during the last quarter. Federated Hermes Inc. raised its position in Mineralys Therapeutics by 100.0% during the second quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock worth $140,000 after acquiring an additional 6,000 shares in the last quarter. PDT Partners LLC acquired a new stake in Mineralys Therapeutics in the third quarter valued at $148,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Mineralys Therapeutics in the 2nd quarter valued at about $145,000. 84.46% of the stock is owned by institutional investors and hedge funds.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.